A Phase I Multicenter Study of the Safety, Tolerability, Viral Shedding Profile, and Immunogenicity of a Recombinant, Live, Attenuated Respiratory Syncytial Virus Subgroup A Strain, rA2cp NS2 in Adults, RSV-Seropositive 15 to 59 Month Old Children, and RSV-Susceptible Children (Seronegative 6 to 24 Month Old Children and Unscreened 4 to 5 Month Old Children) (D133-P7) Wyeth Lederle Vaccines

Trial Profile

A Phase I Multicenter Study of the Safety, Tolerability, Viral Shedding Profile, and Immunogenicity of a Recombinant, Live, Attenuated Respiratory Syncytial Virus Subgroup A Strain, rA2cp NS2 in Adults, RSV-Seropositive 15 to 59 Month Old Children, and RSV-Susceptible Children (Seronegative 6 to 24 Month Old Children and Unscreened 4 to 5 Month Old Children) (D133-P7) Wyeth Lederle Vaccines

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2006

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top